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Sequential targeted exome sequencing of 1001 patients
affected by unexplained limb-girdle weakness
A full list of authors and their affiliations appears at the end of the paper.
Purpose: Several hundred genetic muscle diseases have been
described, all of which are rare. Their clinical and genetic
heterogeneity means that a genetic diagnosis is challenging. We
established an international consortium, MYO-SEQ, to aid the
work-ups of muscle disease patients and to better understand
disease etiology.
Methods: Exome sequencing was applied to 1001 undiagnosed
patients recruited from more than 40 neuromuscular disease
referral centers; standardized phenotypic information was collected
for each patient. Exomes were examined for variants in 429 genes
associated with muscle conditions.
Results: We identified suspected pathogenic variants in 52% of
patients across 87 genes. We detected 401 novel variants, 116 of
which were recurrent. Variants in CAPN3, DYSF, ANO5, DMD,
RYR1, TTN, COL6A2, and SGCA collectively accounted for over
half of the solved cases; while variants in newer disease genes, such
as BVES and POGLUT1, were also found. The remaining well-
characterized unsolved patients (48%) need further investigation.
Conclusion: Using our unique infrastructure, we developed a
pathway to expedite muscle disease diagnoses. Our data suggest
that exome sequencing should be used for pathogenic variant
detection in patients with suspected genetic muscle diseases,
focusing first on the most common disease genes described here,
and subsequently in rarer and newly characterized disease genes.
Genetics in Medicine (2020) https://doi.org/10.1038/s41436-020-
0840-3
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INTRODUCTION
Genetic muscle diseases with limb-girdle weakness (LGW) are
highly heterogeneous, rare neuromuscular disorders (NMD).
In addition to the characteristic progressive pelvic and
shoulder girdle muscle weakness, other manifestations may
include respiratory insufficiency, cardiomyopathy, contrac-
tures, and gastrointestinal complications.1 Consequently, these
disorders diminish an individual’s quality of life and can
reduce life expectancy.2 There is a critical need to fully
characterize disease etiology to achieve accurate diagnoses and
offer appropriate genetic counseling and disease management.
Despite 535 genes known to be associated with 955 distinct
NMDs,3 many muscle disease patients still remain genetically
undiagnosed. This is partly because gene-by-gene and small
panel testing strategies are usually dictated by phenotype, leaving
little power for the expansion of disease associations and novel
disease characterizations.4 An unbiased methodology has thus
been sought to enhance standard clinical practices. Consistent
with an increased affordability over the past decade, next-
generation sequencing (NGS) technologies have been integral in
the diagnosis of disorders such as mitochondrial disease among
others.5 Large-scale NGS panels were applied to 504 Italian
undiagnosed muscular dystrophy and myopathy patients,6 and
more recently to 4655 limb-girdle muscular dystrophy (LGMD)
patients in the United States.7 By investigating 93 and 35 NMD
genes, respectively, they achieved a diagnostic rate of 43% and
27%. However, to date no study has been carried out where
exome sequencing (ES) has been applied to similar limb-girdle
cohorts; this allowed us not only to determine the impact that
the panel size has on the detection rate, but also to interrogate
the exomes beyond the known NMD genes.
We describe here the application of sequential targeted
exome sequencing (TES) to a large cohort of undiagnosed
patients presenting with proximal muscle weakness and/or
elevated serum creatine kinase (CK) levels: the MYO-SEQ
project. We established a partnership between academia,
industry, and patient organizations, and developed an
international network that connected over 40 specialist
neuromuscular referral sites. A total of 1001 exomes were
first analyzed for rare pathogenic variants in 169 common
NMD genes, and then in a further 260 genes associated with
rarer muscle conditions. We identify the most common
muscle diseases in this population and suggest that an
increased number of patients can be more rapidly tested and
diagnosed through an appropriate TES approach.
MATERIALS AND METHODS
Patient recruitment
We utilized the infrastructure established by TREAT-NMD
(https://treat-nmd.org/) to recruit 43 NMD referral centers
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from throughout Europe and the Middle East (Figure S1).
Singleton patients matching the inclusion criteria of unex-
plained limb-girdle weakness and/or elevated CK were
included in the project. Informed consent was obtained for
all patients. Anonymized clinical information was entered on
the PhenoTips platform (https://phenotips.org/) using NMD-
specific forms. Clinical features, histological findings, electro-
myography results, CK levels, mode of inheritance, and
disease onset and progression were recorded using Human
Phenotype Ontology terms. DNA samples were submitted to
the Newcastle Medical Research Council (MRC) Centre
Biobank for Neuromuscular Diseases for which ethical
approval was granted by the National Research Ethics Service
(NRES) Committee North East–Newcastle & North Tyneside
1 (reference 08/H0906/28).
Exome sequencing, data analysis, and interpretation
ES was performed at the Broad Institute of MIT and
Harvard’s Genomics Platform (Cambridge, MA, USA) using
a 38-Mb targeted Illumina exome capture, as described
previously.8 Data were first filtered for variants in 169 NMD-
causing genes (Table S1), with a minor allele frequency in the
ExAC control population9 of ≤1% and a moderate to high
Ensembl Variant Effect Predictor. The resulting shortlists of
single-nucleotide variants (SNVs) and small insertions/
deletions (indels) were examined for pathogenicity by two
independent data analysts (M.B./J.D./K.J./M.M./A.T. at the
John Walton Muscular Dystrophy Research Centre
[JWMDRC] and L.X./E.M.E./E.V./T.M. at the Broad Insti-
tute). We deemed SNVs and indels pathogenic if they had
been previously and consistently reported as pathogenic in
ClinVar (two gold stars review status; https://www.ncbi.nlm.
nih.gov/clinvar/) and/or published literature. In line with
American College of Medical Genetics and Genomics
(ACMG) guidelines,10 pathogenicity of novel variants was
evaluated based on (1) computational data, i.e., predicted to
be deleterious by all, or the majority, of the in silico tools used;
(2) population data, i.e., have a frequency in the control
population compatible with the variant being rare disease-
causing, according to its inheritance mode; and (3) allelic
data, i.e., be in trans with a pathogenic variant; however, as
phase could rarely be established for putative compound
heterozygous cases we refer to these as double heterozygous.
Variants of uncertain significance are not discussed here. To
be considered solved, a patient was required to carry two
known or suspected pathogenic variants in a recessive gene, or
(at least) one known or suspected pathogenic variant in a
dominant gene. By suspected pathogenic variants we refer to
rare and damaging variants identified in a gene associated
with a disease that matches the patients’ clinical presentation,
disease onset and progression, magnetic resonance image
(MRI) findings, and/or muscle histopathology. The findings
were disclosed to the submitting centers in tailored reports,
signposting the patients to relevant disease registries. Where
necessary and possible, the suspected pathogenic variants
were confirmed and segregated through Sanger sequencing,
muscle biopsies further investigated, and clinical histories
reassessed by the referring clinicians (Figure S2).
The remaining unsolved cases were subsequently analyzed
for likely pathogenic variants in a further 260 genes (Table S2)
including those associated with neuropathies, cardiomyopa-
thies, and other phenotypes presenting with muscle weakness
to identify rarer neuromuscular conditions. This extended
gene list also included genes newly associated with muscle
disease. ES data were also analyzed for copy-number variants
(CNVs)11 and SMN1 exon 7 deletions12 (Supplementary
Materials and Methods). For those cases carrying a single
heterozygous pathogenic variant in the most common
(exclusively recessive) genes found in our cohort (i.e., CAPN3,
DYSF, ANO5, and SGCA) we further interrogated the
noncoding regions of the gene captured in the ES data. In
addition, for the DYSF carriers we Sanger sequenced two
previously reported pathogenic intronic variants.13 Finally,
one patient was also subjected to genome sequence (GS) and
RNA sequencing (RNA-Seq), as described elsewhere.14
RESULTS
Demographics of 1001 patients with suspected genetic
muscle disease
One thousand and one patients were recruited into the MYO-
SEQ project, with the majority (93%) inferred to be of
European or Middle Eastern ancestry. The study cohort
comprised 545 (54%) males and 456 (46%) females and
originated from 972 families. Disease onset for 42% of the
patients was in adulthood (Figure S3A) and the mean age at
the time of recruitment was 39 years (Figure S3D). Proximal
muscle weakness, either in isolation or with distal muscle
weakness, affected most participants (77%; Figure S3B), while
68% of the cohort had increased serum CK levels (Figure S3C).
Based on family history, 46% of patients were sporadic cases,
while 14%, 7%, and 1% showed recessive, dominant, and X-
linked inheritance, respectively; for the remaining 32%, no
indication of inheritance pattern was stated by the referring
clinician.
Initial screening detected suspected pathogenic variants in
47% of participants
Using the World Muscle Society gene table (http://www.
musclegenetable.fr/) we generated a list of 169 genes known to
be associated with limb-girdle muscle disease (Table S1) and
initially restricted our search for likely causal variants to only
these genes. As a result, 468 patients (47%) had rare known or
suspected pathogenic variants across 72 genes that we
considered were causal; these cases were deemed solved
(Table 1, Fig. 1).
Frequency of NMD genes varied greatly in our cohort
The most common disease in our cohort was LGMD R1
calpain3-related, caused by autosomal recessive pathogenic
variants in CAPN3. Variants in CAPN3 and seven other genes
—DYSF, ANO5, DMD, RYR1, TTN, COL6A2, and SGCA—
accounted for over half of the solved cases (n= 260). The
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other 208 solved cases had suspected pathogenic variants
across 64 additional genes. Importantly, we identified a stop-
gain TTN founder pathogenic variant (p.[Gln35879Ter]) in 14
patients from a Serbian subpopulation.8 Without this variant,
TTN would be outnumbered by COL6A2 and COL6A3
(collagen VI–related myopathies), SGCA (LGMD R3 α-
sarcoglycan–related), and FLNC (myofibrillar myopathy 5
and distal myopathy 4). Some diseases were notably absent
from our cohort; for example, no POMGnT1 (LGMD R15
POMGnT1–related) or ISPD (LGMD R20 ISPD-related)
patients were identified, highlighting the extreme rarity of
these diseases. When the data were stratified by sex, there
appeared to be a skewed ratio of males (n= 22; 69%) to
females (n= 10; 31%) harboring suspected pathogenic
variants in ANO5 (p < 0.0691), confirming previously
reported findings.15
Homozygous variants associated with established
autosomal dominant inheritance
A proband from a consanguineous pedigree harbored a
previously reported dominant pathogenic variant (c.476G>A
p.[Arg159His]) in VCP in homozygosity, while another
proband carried a novel homozygous variant (c.1325C>G p.
[Pro442Arg]) in FLNC; both genes have established autosomal
dominant inheritance. In both cases, the clinical presentation
was in keeping with what was expected, but at the more severe
end of the spectrum with an earlier disease onset. Both sets of
parents were heterozygous for the respective variants. The
mother of the homozygous VCP patient remained asympto-
matic at the time of examination, while the father presented
with proximal weakness and atrophy of the upper and lower
limbs, and rimmed vacuoles on histopathology,16 as would be
expected for this previously reported dominant variant.17 On
the other hand, the parents of the homozygous FLNC patient
were both clinically unaffected on examination. This would
suggest a different pathological mechanism for this novel
FLNC variant and functional work is underway (unpublished
data by University Duisburg–Essen).
Solved rate differed with geographical location of the
participating center
When the data were stratified by geographic location, there
was a clear distinction between regions with and without the
infrastructure to sufficiently prescreen patients prior to
submission. The detection rate for referring centers in Eastern
Europe and the Middle East was as high as 95%, including, for
example, 57 LGMD R1 calpain3-related and 32 LGMD R2
dysferlin-related cases. Conversely, the detection rate for
Western Europe was as low as 35%, with only 23 LGMD R1
calpain3-related (p < 0.00001) and 15 LGMD R2 dysferlin-
related cases (p < 0.00001), and a larger proportion of rarer
genes and phenotypes (Fig. 2).
Table 1 Breakdown of genes in which suspected causal variants were identified in the MYO-SEQ cohort.
Gene Number of patients Gene Number of patients Gene Number of patients Gene Number of patients
CAPN3 78 POGLUT1a 5 PYROXD1a 2 HSPB1a 1
RYR1 26 SCN4A 5 SGCB 2 HSPB8a 1
DYSF 45 CLCN1 3 ACADVL 1 INPP5Ka 1
ANO5 33 DNM2 4 BAG3 1 LPIN1 1
DMD 31 MYOT 4 BVESa 1 MATR3 1
TTN 25 RAPSN 4 CACNA1Sa 1 MGME1a 1
COL6A2 17 DNAJB6 3 CHRND 1 MMEa 1
SGCA 16 GMPPB 3 COL12A1 1 MYF6 1
COL6A3 12 MTM1 3 CPT2 1 MYH14 1
FLNC 12 SEPN1 3 CRYAB 1 NEB 1
DES 10 TCAP 3 DOK7 1 PFKM 1
GAA 10 TRAPPC11 3 DPM3 1 PGK1 1
LAMA2 10 ACTA1 2 DYNC1H1a 1 POLG 1
POMT2 10 AGL 2 EGR2a 1 PTPLA 1
COL6A1 10 ATP2A1 2 ETFDH 1 SYNE2 1
LMNA 9 COLQ 2 FKTN 1 TMEM8Ca 1
MYH7 9 FHL1 2 GBE1 1 TNNT3 1
FKRP 8 PHKA1 2 GFPT1 1 TPM2 1
SGCG 8 POMK 2 GNE 1 TTRa 1
SMCHD1 8 POMT1 2 GYG1 1 VCP 1
TRIM32 7 PRPS1a 2 HNRNPA1a 1 VMA21 1
CAV3 5 PYGM 2 HNRNPDL 1
Suspected causative variants were identified in 87 genes in 489 patients: 72 genes during the first round of analysis using a gene list of 169 neuromuscular disorder
(NMD) genes, and 15 additional genes when using a gene list extended by a further 260 NMD genes.
aFifteen additional genes identified.
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Analysis of an extended gene list increased the diagnostic
yield to 49%
For the remaining unsolved cases, we extended the analysis to
a total of 429 disease-causing genes (Table S2). This resulted
in a 2% increase in detection rate to an overall 49% (n= 488),
across 87 muscle disease–associated genes; 15 genes more
than the initial analysis. These genes were associated with
neuropathies (EGR2, DYNC1H1, HSPB1, HSPB8, PRPS1, and
MME), multisystemic disorders presenting with muscle
weakness (HNRNPA1, INPP5K, TMEM8C, and TTR), chan-
nelopathies (CACNA1S), and mitochondrial disease
(MGME1), all detected in patients who had been initially
clinically diagnosed as LGW (n= 12). In addition, three genes
only recently associated with muscular dystrophy (BVES and
POGLUT1)18,19 and myofibrillar myopathy (PYROXD1)20
were found in eight patients. Thus, after the eight most
common disease genes, accounting for 25% of the full cohort,
the next ten genes (COL6A3, FLNC, DES, GAA, LAMA2,
POMT2, COL6A1, LMNA, MYH7, and FKRP) account for an
additional 10%, followed by a very small but nonetheless
meaningful increase in solved rate as very rare and/or
unexpected disease genes, as well as those recently described,
are detected (Table 1).
Expanding exome sequencing beyond single base pair
changes and small indels increased the detection yield by a
further 3%
Further to point variants and small indels, we detected
suspected pathogenic CNVs in 26 (3%) additional patients. Of
these, 17 carried copy-number zero deletions (at exon or
multiexon level) in autosomal recessive genes (DYSF, SGCA,
SGCB, SGCD, SGCG, and LPIN1; n= 10) and in X-linked
genes (DMD, EMD, and FHL1; n= 7, all males). Eight cases
carried a heterozygous CNV in combination with a suspected
pathogenic SNV in the same gene and one case, presenting
with a classical dominant myofibrillar myopathy phenotype,
CAPN3 8%
DYSF 4%
ANO5 3%
DMD 3%
RYR1 2%
TTN 2%
COL6A2 2%
SGCA 2%
Unsolved
48%
One gene - other
19%
Two genes
2%
CNV
3%Extended gene list
2%
SMN1 deletion
0.5%
Transcriptomics and GS
0.1%
Fig. 1 Summary of the solved rate and sequential analysis in the MYO-SEQ cohort. Suspected pathogenic variants were detected in a total of 520
patients (52%). Initially, 468 (47%) patients were solved through a screening of the MYO-SEQ gene list of 169 neuromuscular disorder (NMD) genes; of
these, 450 (45%) had pathogenic variants in one of 72 genes and 18 (2%) had pathogenic variants in two genes. Pathogenic variants in eight of these
genes alone accounted for half of the solved patients (26%); the most common disease detected in our cohort was limb-girdle muscular dystrophy (LGMD)
R1 calpain3-related (CAPN3). Variants in 64 genes accounted for the remaining patients with one causal gene. The analysis strategy was extended by a
further 260 genes, solving an additional 2% of the cohort. Copy-number variations (CNVs) were detected in 26 (3%) patients, SMN1 deletions in five
(0·5%) patients and transcriptional perturbations in one patient. n= 1001. GS genome sequencing.
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carried a heterozygous deletion in DES. Some of these CNVs
were recurring; we identified a 10.4-kb deletion in CAPN3 in
five unrelated patients, and a 0.7-kb and 0.12-kb deletion in
SGCD and SGCG, respectively, in two unrelated patients each
(Table S3). In addition, we looked for homozygous deletions
of exon 7 in SMN1, causative of spinal muscular atrophy.
Such deletions were detected in five patients (0.5%), all of
which were confirmed by multiplex ligation-dependent probe
amplification (MLPA). Finally, through additional RNA-Seq
and GS, we were able to identify an intronic change resulting
in a 73-bp intron inclusion in DMD leading to a premature
stop codon in one patient with a clear Becker-like phenotype
and supporting family history, but with no evident causal
exonic DMD variant,14 highlighting that strong phenotypic
clues should always be followed up.
Over 400 novel suspected pathogenic variants were
identified
In total, we identified 865 SNV and indel changes in 429
genes that were most likely to contribute to the 496
participants’ diseases. A breakdown of the genotypes and
types of variants is shown in Fig. 3a, b. The 865 variants were
accounted for by 520 distinct variants (Table S4); of these, 119
had been submitted to ClinVar previously, while the
remaining 401 were novel and had not been yet reported at
the time of the analysis (Fig. 3c). Of the novel variants, 285
were seen only once and, notably, 116 were seen multiple
times in our patient population (Fig. 3d). These novel variants
will be submitted to ClinVar to aid future genetic diagnoses.
Single heterozygous pathogenic variants in the most
common recessive genes account for 2.5% of the unsolved
cases
To unravel the remaining unsolved patients, we looked at
those who carried single reported pathogenic variants in the
four most common exclusively recessive genes found in our
cohort. We found 25 (2.5%) heterozygous carriers: 13 CAPN3,
9 ANO5, 2 SGCA, and 1 DYSF. These cases were accounted
for by 16 pathogenic variants: 10 CAPN3, 4 ANO5, 1 DYSF,
and 1 SGCA. These variants were all more frequent in our
cohort of patients than in the control population. For
example, a rare SGCA variant (c.229C>T; p.[Arg77Cys])
occurred four times more frequently in the disease population
(p= 0.02), the common Eastern European CAPN3 variant
(c.550delA; p.[Thr184ArgfsTer36]) over eight times more
(p= 0.00028), and the European founder ANO5 variant
(c.191dupA; p.[Asn63fs]) almost five times more (p=
0.00016). This suggests that these variants are likely to play
Fig. 2 Solved rate by country of origin. The MYO-SEQ solved rate (in dark gray) was higher in countries such as Egypt and Turkey where the
infrastructure for genetic testing for prescreening is not as widely available, and lower in Western European countries where genetic prescreening of
common limb-girdle muscular dystrophy (LGMD) genes is routinely performed. Calculated for referring centers submitting more than 20 samples.
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Fig. 3 Breakdown of the suspected pathogenic variants and genotypes in the MYO-SEQ cohort. (a) Zygosity of the solved patients’ variants (n=
506; 489 patients, 20 with an additional gene to report). (b) Type of variants suspected to be pathogenic. Initiation and stop loss occurred twice each (n=
865). (c) The 865 occurrences were accounted for by 520 distinct variants, of which 119 were reported as pathogenic in ClinVar and 401 were novel in their
association to disease at the time of the analysis. (d) Of the 119 distinct variants reported in ClinVar, 70 were detected in only one individual (unique) while
49 were detected in multiple patients. Of the 401 distinct variants that were novel in their association to disease, 285 were detected in only individual cases,
while 116 were detected in multiple families.
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a role in disease manifestation and that a second cryptic
disease-causing variant might not have been detected by our
analysis; we therefore interrogated these carriers further by
looking into the noncoding regions present in their exome
data. We thus identified one novel 3′ UTR and two rare
CAPN3 intronic variants, one of which (c.1746–20C>G)
occurred in three cases. Histopathological analysis showed
markedly reduced calpain3 immunostaining, suggesting that
this noncoding variant may affect splicing or protein stability.
In addition, we identified an intronic deletion
(c.585–31_585–24delTCTGCTGA) in one of the SGCA
carriers, which results in partial expression of the α-
sarcoglycan protein.21 Conversely, none of the reported
pathogenic intronic variants in DYSF13 were found in the
DYSF carrier.
Many patients harbored suspected pathogenic variants in
genes associated with treatable or manageable conditions
Our study identified 64 patients (6.5%) that might benefit
from treatment or specific management options related to
their diagnosis. For example, variants in COLQ, DOK7,
GFPT1, and RAPSN—all associated with congenital myasthe-
nic syndrome (CMS)—were identified in eight patients (<1%).
We also identified ten patients (1%) with compound
heterozygous variants in GAA, associated with Pompe
disease.22 Nine patients (1%) harbored variants in either
SCN4A or CLCN1 and thus were suspected to have ion
channel disorders that could benefit from selective drug
interventions. We identified 13 female patients (1%) who
were likely to be manifesting carriers of Duchenne muscular
dystrophy, an X-linked disorder that often escapes clinical
diagnosis in females. Finally, we identified 24 patients (2%)
with heterozygous suspected pathogenic variants in RYR1,
which can confer susceptibility to malignant hyperthermia.
DISCUSSION
We sought to improve the diagnostic pathway of patients with
limb-girdle muscle diseases by implementing TES as a first-
pass diagnostic strategy. By focusing on 429 NMD genes
within the exome data, we solved 49% of our cohort,
comparable with equivalent NGS panel studies.6,7 A small
number of common NMD genes, namely CAPN3, DYSF,
ANO5, DMD, RYR1, TTN, COL6A2, and SGCA accounted for
more than half of the solved cases. Our finding that LGMD
R1 calpain3-related was the most common LGMD in our
cohort is in agreement with other European studies.6 Standard
calpain3 immunoblot testing can only achieve a low
sensitivity,23 which could explain why a tenth of the MYO-
SEQ cohort was not diagnosed with this LGMD prior to
enrollment. Moreover, many of the calpain3-related patients
were referred from centers without the technical infrastruc-
ture to prescreen their patients.
Given the considerable phenotypic overlap and the rarity of
some of these muscle conditions, it is almost impossible for
clinicians, however expert, to individually diagnose every
disease. Some of the LGMDs, such as R15 POMGnT1-related
and R20 ISPD-related, were absent from our cohort. No SNVs
and only one CNV were identified in the SGCD gene, in
keeping with other sequencing projects from China (n=
756),24 Italy (n= 504),6 and the United States (n= 4656)7
where no SGCD variants were found. Interestingly, LGMD R6
δ-sarcoglycan–related patients accounted for >1% of the
diagnosed cases in a South American cohort (n= 2103),25
highlighting that the geography-specific prevalence of some
diseases should be considered during clinical work-ups. Per
sex bias, we corroborated previous findings that ANO5
diagnosis is more frequent in males.15 This is likely due to
the milder, sometimes asymptomatic, presentation of LGMD
R12 anoctamin5-related in females; because of this, females
can present to clinic much later in life, or not at all, skewing
the diagnostic rate in favor of males.
The relatively small benefit observed when extending the
gene list from 169 to 429 genes is in line with a panel study of
700 NMD genes where exome sequencing of the remaining
undiagnosed cases did not improve the pick-up rate for known
NMD genes.26 However, having exome data available, such as
in our study, allows for both gene discovery and data analysis
reiteration when new disease genes are characterized, neither
of which are possible even with a large NGS panel approach.
This was the case for the BVES, POGLUT1, and PYROXD1
patients who were missed in the first round of analysis, as the
genes had not yet been described as disease-causing. By
interrogating the whole exome of the unsolved patients, we
identified and have functionally characterized two novel genes,
one associated with a rare secondary dystroglycanopathy and
the other, POPDC3, found in three unrelated individuals,
associated with a typical LGMD phenotype.27 Two additional
novel candidate genes are under investigation and we expect
that this will only increase as the exome data of unsolved
patients are more intricately examined.
It is possible that further causative variants have not been
assigned pathogenicity due to the limitations of proband-
only analysis or that they have not been detected due to
nonuniform coverage and/or poorly designed capture baits
that might not target relevant tissue-specific exons. For
example, repeat regions in NEB or TTN are known to be
difficult to map to the genome and therefore variants in
these regions are poorly called.28 Somatic mosaicisms,29
only detected by deep coverage sequencing, would also have
been missed. A further proportion of the remaining
unsolved cases might be caused by genetic changes in
intergenic, intronic, or regulatory regions not covered by ES.
The overrepresentation in our disease cohort of carriers of
known pathogenic variants in recessive genes likely implies
that a second cryptic variant is yet to be detected. In fact,
when interrogating these cases further we identified
recurrent suspected pathogenic intronic variants and CNVs.
Otherwise, these pathogenic heterozygous variants might
act as disease modifiers, contributing to the disease severity
or progression.30
Using modified pipelines, we have identified several disease-
causing CNVs, accounting for 3% of the diagnoses. However,
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more complex structural variants such as translocations and
inversions, would not have been detected.31 In a similar
manner, tri- and tetranucleotide expansion repeats, such as
the cause of some adult onset neuromuscular conditions (e.g.,
myotonic dystrophy), are typically missed in standard short-
read NGS data. Interestingly, four unsolved cases were
reported to present with myotonia, percussion myotonia, or
myotonic discharges. Other novel late-onset myopathies
might be caused by similar mechanisms and long-read NGS
would be needed to identify them. Digenic or non-Mendelian
inheritance, such as genomic imprinting, may also account for
a proportion of the undiagnosed patients32,33 and will need a
different methodological and analytical strategy.
It is also possible that some of the unsolved patients may
have acquired forms of muscle disease, such as acquired
immune, inflammatory, noninflammatory, or even statin-
induced myopathies. In fact, during the project four patients
(<1%) obtained a confirmed diagnosis of inclusion body
myositis. Regular screening for anti-NT5c1A and anti-
HMGCoR should provide a more realistic indication of the
prevalence of these diseases in the affected population.
Over 6% of our patients received a genetic outcome that
resulted in specific monitoring and tailored treatments. For
example, for the CMS patients, genetic diagnoses were vital
to provide adequate treatment, as this depends on the
disease subtype and causative gene. Indeed, the referring
clinicians reported that these patients all showed marked
improvement after appropriate treatments were com-
menced. The pathogenicity of the RYR1 variants could not
always be fully confirmed, yet it was prudent to return these
potential diagnoses to physicians to manage possible risk of
malignant hyperthermia. For most of the solved cases,
however, who might not benefit from specific treatment,
their genetic diagnosis will nevertheless allow appropriate
family planning, counseling, and monitoring of their
diseases.
MYO-SEQ was a worldwide partnership between acade-
mia, industry, and patient organizations. Frequent commu-
nication with the referring physicians was essential for the
success of the project; to reach a meaningful diagnosis,
interpretation of the genetic data was always in the context
of clinical, histopathological, and MRI data. The participat-
ing centers provided consent for data sharing facilitated by
the European Genome-Phenome Archive (EGA) and RD-
Connect (https://platform.rd-connect.eu/), and we advocate
that adopting such an approach will enable future
matchmaking between extremely rare cases, such as BVES-
related myopathy34 or LGMD R21 POGLUT1-related.35 In
addition, thanks to the large cohort size and standardized
deep phenotypic data, we were able to expand the clinical
and mutational spectrum of known causative genes,
such as TRIM32,36 POMK,37 DPM3,38 POMT2,39 and other
dystroglycanopathies.40
Based on our findings from this large-scale international
collaboration, we suggest a new diagnostic approach in the
clinic and/or private health providers. Rather than imple-
menting small NGS panel approaches, led by phenotypic clues
that can often be misleading due to the high clinical
heterogeneity of muscle diseases, patients should be directly
referred for exome sequencing. The exome sequencing data of
NMD patients of European and Middle Eastern origin should
first be promptly analyzed for pathogenic variants in the eight
genes most commonly associated with muscle disease in our
cohort—CAPN3, DYSF, ANO5, DMD, RYR1, TTN, COL6A2,
and SGCA. This is expected to diagnose over a quarter of
individuals. The analysis pipeline should then be extended to
include additional NMD genes, enabling a diagnosis in a
further quarter of patients. For those patients who remain
undiagnosed, their ES data can be further interrogated.
Importantly, exome data can be retrospectively and repeatedly
analyzed for pathogenic variants in novel disease genes as new
discoveries are made, making it a much more cost-effective
approach.
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